Introduction
Community-acquired pneumonia (CAP) is an important public health problem worldwide. Despite continuing improvements in aetiological diagnosis, effective antibiotic treatment and advances in supportive care, mortality rates in patients with CAP remain high. 1, 2 The most common causative bacterial pathogen of CAP is Streptococcus pneumoniae, which also is the most frequent aetiology associated with death in CAP patients. 1 -4 Broad empirical coverage in CAP is recommended by current guidelines to cover the most frequent aetiologies. 1, 5 The same CAP guidelines encourage attempts to broaden, narrow or completely modify the spectrum of antibiotic therapy on the basis of diagnostic test results. Traditional microbiological investigations in CAP include good-quality sputum and blood cultures. Rapid tests based on urinary detection of pneumococcal and Legionella antigens and nucleic acid amplification techniques, which provide early diagnosis and allow prompt appropriate antibiotic treatment, are increasingly used today. 6, 7 In recent years, antibacterial resistance has been accelerating at an alarming pace, leading to a global increase in morbidity and mortality. 8, 9 It is recognized that antimicrobial stewardship must be a key component of attempts to reduce costs and adverse drug events and to deal with the threat of antibiotic resistance. 6, 10 A variety of strategies may be utilized in stewardship programmes to optimize the management of CAP and improve patient outcomes. 11, 12 These include a rational use of antibiotic deescalation, administering an appropriate pathogen-focused agent or narrowing empirical therapy. In this regard, a recent study reported that de-escalation therapy among bacteraemic patients with CAP, mainly due to S. pneumoniae, non-fermenters and Enterobacteriaceae Gram-negative bacteria, was not associated with an increased risk of 30 day mortality. 13 However, many aspects are still to be defined, such as the effect of de-escalation therapy on other important CAP clinical outcomes including length of hospital stay (LOS), adverse events and readmission rates, and in the case of patients with severe disease.
The aims of our study were to assess the impact of antibiotic de-escalation on clinical outcomes in patients with communityacquired pneumococcal pneumonia (CAPP). We also specifically evaluated the de-escalation impact in patients classified into high-risk pneumonia severity index (PSI) classes (IV -V), clinically unstable patients and those with bacteraemia.
Methods

Study design
This study was conducted at Hospital Universitari de Bellvitge -IDIBELL, a 700 bed public hospital in Barcelona, Spain. All adult patients admitted to hospital with CAPP via the emergency department from 1 February 1995 to 31 December 2014 were prospectively followed-up. Patients who died within the first 72 h after hospital admission and those who had already received penicillin, amoxicillin or amoxicillin/clavulanate were excluded.
At hospital admission, patients underwent a complete clinical history and physical examination. Microbiological studies included two sets of blood cultures and sputum Gram's stain and culture when available. Urinary antigen detection for S. pneumoniae was performed if indicated by the attending doctor. Patients were stratified into risk classes by the PSI score, as described elsewhere.
14 They were seen daily during their hospital stay by one or more of the investigators who recorded clinical, laboratory and microbiological data in a computer-assisted protocol.
Empirical antibiotic treatment was applied according to hospital guidelines, which recommend the administration of a b-lactam agent (ceftriaxone or amoxicillin/clavulanate) with or without a macrolide or a fluoroquinolone. Combination treatment was recommended for patients with clinical suspicion of Legionella or an atypical pathogen, or in the case of severe pneumonia in the absence of a demonstrative sputum Gram's stain. There was no official hospital policy concerning de-escalation.
Definitions
CAPP was diagnosed as described elsewhere. 4 Briefly, patients with signs and symptoms of acute-onset respiratory tract infection, new infiltrate on chest X-ray, one or more cultures positive for S. pneumoniae obtained from blood, normally sterile fluids or sputum, and/or a positive urinary antigen test were diagnosed with CAPP. S. pneumoniae was identified using standard microbiology procedures. From 2000 onwards, urinary antigen detection using a rapid immunochromatographic assay (Binax Now, Binax, Portland, ME, USA) for S. pneumoniae was also available. Clinical stability was defined when the patient met the following objective criteria: ability to maintain oral intake; stable vital signs (considered as temperature ,37.88C, respiratory frequency ,24 breaths/min, systolic blood pressure 90 mm Hg without vasopressor support); absence of exacerbated major comorbidities (i.e. heart failure, chronic obstructive pulmonary disease) and/or septic metastases, baseline mental status, and adequate oxygenation on room air (PaO 2 60 mm Hg or pulse oximetry 90%). For patients with chronic hypoxemia or receiving chronic oxygen therapy, PaO 2 or pulse oximetry measurement had to be similar to their baseline values. 15 For the purposes of this study patients were divided into two groups: those with treatment de-escalation and those without treatment de-escalation within 72 h of hospital admission (henceforth 'de-escalation group' and 'non-de-escalation group'). De-escalation was considered when the initial antimicrobial spectrum was narrowed to penicillin, amoxicillin or amoxicillin/clavulanate within 72 h of hospital admission, by which time the microbiological test results were usually known.
The primary outcome measures were 30 day mortality and LOS. Thirty day mortality was defined as death due to any cause during ≤30 days of hospitalization, and LOS was measured in days from the documented time of admission to the documented time of discharge. Prolonged LOS was defined as an LOS greater than the median (in days). The secondary outcomes were the days of duration of intravenous (iv) antibiotic therapy, the occurrence of adverse events and the subsequent hospital admission. All inpatient antibiotic administration was verified through the paper-based medical administration record.
Ethics
Written informed consent was considered not necessary for the study, as it was a prospective analysis of our usual everyday work. The data of the patients were anonymized for the purposes of this analysis. Confidential patient information was protected according to national standards. This manuscript has been revised by the Clinical Research Ethics Committee of Bellvitge University Hospital (PR070/16).
Statistical analysis
To detect significant differences in clinical, laboratory and outcomes between de-escalated and non-de-escalated groups, we used the x 2 test or Fisher's exact test for categorical variables, and Student's t-test or the Mann -Whitney U-test for continuous variables, when appropriate. The multivariate analysis of factors potentially associated with primary and secondary outcomes included all the statistically significant variables in the univariate analysis and other variables with clinical relevance, including the de-escalated group. Model fit was evaluated with the HosmerLemeshow goodness-of-fit test. We used the stepwise logistic regression model of the SPSS software package (SPSS, version 13.5; SPSS, Chicago, IL, USA). An a priori subgroup analysis was performed in patients classified into high-risk groups according to the PSI (classes IV-V) at admission, in those without clinical instability and in those with bacteraemia.
Moreover, the probability that a patient has been de-escalated was assessed with multivariate analysis including the factors that might influence the decision to de-escalate antibiotic treatment. This multivariate model was used to create a propensity score for each patient. A multivariate analysis for primary and secondary outcomes was performed adjusting for the propensity score within the model. Statistical significance was established at a¼0.05. All reported P values are two-tailed.
Results
Patient characteristics
A total of 1410 consecutive episodes of CAPP were analysed. The microbiological methods used to establish the diagnosis of CAPP were Gram's stain and sputum culture in 472 patients, blood cultures in 410, urinary antigen test in 927, and others (tracheal aspirate, transcutaneous puncture, bronchoscopy) in 59. Diagnosis was made with two or more of these tests in 424 patients. Patients who received initially penicillin, amoxicillin or amoxicillin/clavulanate were excluded (n ¼ 127). Inappropriate escalation therapy was given to 62 patients, and 1055 received partial reduction of antimicrobial spectrum (not penicillin, amoxicillin or amoxicillin/ clavulanate) or continued high-spectrum antibiotic therapy without changes. The 30 day mortality (excluding patients who died in the first 72 h) was 5.1% (72 patients), the median LOS was 8 days (IQR, 6 -12 days) and the median duration of iv antibiotic therapy was 5 days (IQR, 3-8 days).
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There were 166 patients in the de-escalation group and 1117 patients in the non-de-escalation group. There was a higher frequency of antibiotic de-escalation within 72 h of hospital admission over the years (from 1.1% in 1995 -2000 to 17.8% in 2010 -14) and the LOS did not decrease significantly over the time. No significant differences were documented in age, sex or comorbidities between the two study groups (Table 1) . Regarding clinical features and laboratory findings, patients in the de-escalated group less frequently had hypotension, tachycardia, multilobar pneumonia on chest X-ray, empyema and bacteraemia. In addition, these patients were less commonly classified into the high-risk PSI groups. Penicillin-resistant S. pneumoniae was found in 27 patients, but there were not significant differences between study groups (P ¼ 0.73).
Effect of antibiotic de-escalation on outcomes
Outcomes by study group are shown in Table 2 . In univariate analysis, 30 day mortality, LOS (above the median .8 days) and duration of iv antibiotic therapy (above the median .5 days) were significantly lower in the de-escalation group. Moreover, the number of patients with adverse drug reactions or who required readmission (,30 days) was similar in the two groups. No patient developed Clostridium difficile-associated diarrhoea.
After adjustment for confounding factors, antibiotic deescalation was not associated with a higher risk of mortality in the multivariate analysis (Table 3) . Moreover, antibiotic deescalation was a protective factor for prolonged LOS (Table 4) and prolonged duration of iv antibiotic therapy (Table 5 ).
Subgroup analysis
Assessment of CAPP severity resulted in 835 patients being classified into high-risk PSI classes. In the univariate analysis, antibiotic de-escalation was not associated with higher risk of mortality (3.1% versus 8.1%; P ¼0.08). It was linked with a lower risk of prolonged LOS (26% versus 55.9%; P,0.001) and prolonged duration of iv antibiotic therapy (13.5% versus 54.4%; P,0.001). 
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Data about time from hospital admission to clinical stability were available for 997 patients. Clinical stability was not achieved within 72 h of hospital admission in 559 patients. In this subgroup of patients, in the univariate analysis, antibiotic de-escalation was not associated with a higher risk of mortality compared with nonescalation (1.9% versus 5.4%; P ¼ 0.50); however, it was associated with a lower risk of prolonged LOS (40.4% versus 62.2%; P ¼ 0.002) and prolonged duration of iv antibiotic therapy (21.2% versus 66.7%; P,0.001).
Bacteraemia was documented in 373 patients. In the univariate analysis, lower frequencies of mortality (0% versus 9.2%; P ¼ 0.05), prolonged LOS (18.4% versus 59.2%; P, 0.001) and prolonged antibiotic therapy (2.7% versus 55.4%; P, 0.001) were found in the de-escalation group compared with the nonde-escalation group.
Antibiotic de-escalation was not associated with a higher risk of mortality in the multivariate analysis performed in each subgroup. Moreover, multivariate analysis showed that antibiotic de-escalation was not a protective factor for prolonged LOS only in the subgroup of patients with clinical instability (P ¼ 0.08), and it was a protective factor for prolonged duration of iv antibiotic therapy in all subgroups (data not shown).
Propensity score analysis
The propensity score was generated using eight variables that might influence the decision to de-escalate antibiotic treatment (age, comorbid conditions, tachycardia, septic shock, multilobar pneumonia, empyema, bacteraemia and ICU admission) ( Table 6 ). When the propensity score was entered in the multivariate models, antibiotic de-escalation was not associated with Viasus et al.
a higher risk of mortality (OR¼0.83, 95% CI¼0.24-2.81; P¼0.76), but it was a protective factor for prolonged LOS (OR ¼0.46, 95% CI¼0.30-0.70; P,0.001) and prolonged duration of iv antibiotic therapy (OR¼0.15; 95% CI¼0.08-0.26; P,0.001).
Discussion
This study offers a comprehensive evaluation of the effects of antibiotic de-escalation within the first 72 h of hospital admission on outcomes in CAPP. The results suggest that de-escalation therapy was not associated with a higher risk of 30 day mortality, but was associated with a shorter LOS and duration of iv antibiotic therapy. In a recent study, Carugati et al. 13 reported that de-escalation therapy among patients with CAP was not associated with an increased risk of 30 day mortality or clinical failure. However, their study evaluated only CAP patients with Gram-positive and Gram-negative bacteraemia, de-escalation therapy was considered within 7 days of hospital admission, and the number of patients with CAPP was low. Other studies have also evaluated the effects of antibiotic de-escalation in infections due to difficult-to-treat Gram-negative bacilli, 16 neutropenia 17 and urinary tract infections. 18 Antibiotic de-escalation was not associated with an increased risk of mortality in all these studies. Similarly, in a recent multicentre non-blinded randomized noninferiority trial performed in patients requiring ICU admission for severe sepsis, de-escalation therapy was not related to mortality, ICU stay, LOS or duration of mechanical ventilation or vasopressors. 19 In agreement with a previous study, 13 we found that the non-de-escalation group was characterized by a more severe presentation at admission, as evidenced by higher frequencies of hypotension, tachycardia, multilobar pneumonia on chest X-ray and bacteraemia. In the present study, after adjustment for confounders in multivariate and propensity score analyses, we found that antibiotic de-escalation was not associated with an increased risk of 30 day mortality in patients with CAPP. Evaluating other important clinical outcomes in CAP, our results suggest that antibiotic de-escalation was independently associated with shorter duration of LOS. No significant differences were found regarding adverse drug reactions or readmission (,30 days) between study groups.
In an era of cost containment and resource constraints in many healthcare systems, adequate resource allocation and cost-effective healthcare delivery are of paramount importance. 20 The economic burden associated with CAP remains substantial, and LOS is the most important cost driver of hospitalization. 21 A recent study in the US estimated that reducing the course of a CAP admission by 1 day may represent a saving of $2273 -2373. 22 Therefore, our finding of shorter LOS in patients with CAPP who underwent de-escalation therapy may have significant economic implications.
There is a concern about performing antibiotic de-escalation in patients with severe disease or in patients who are not clinically stable. To date, therapy de-escalation has not been assessed in these CAP patients. In the present study, we found antibiotic de-escalation to be safe in patients classified into high-risk PSI classes, and no increase in mortality was observed. Similar results were found if antibiotic de-escalation was performed in patients who remained clinically unstable during the first 72 h after hospital admission. Our results suggest that antibiotic de-escalation also seems to be safe among these subgroups of CAPP patients. However, it is important to note that only 159 patients did not reach clinical stability within 72 h of hospital admission and only 2 patients in the de-escalation group were admitted to the ICU.
In recognition of the fact that antimicrobial resistance results in increased morbidity, mortality and cost of healthcare, a series of guidelines has been published for improving the use of antimicrobial agents in hospitals. 10 A comprehensive evidence-based stewardship programme to combat antimicrobial resistance includes streamlining or de-escalating antimicrobial therapy towards more targeted therapies that decrease antimicrobial exposure and contain cost. The Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of CAP in adults recommends antibiotic deescalation as best medical practice, 1 but the evidence available in support of this recommendation is scarce. Our study shows that antibiotic de-escalation to penicillin, amoxicillin or amoxicillin/clavulanate is safe among patients with CAPP. Significantly, we did not consider de-escalation or narrowing of antibiotic therapy to third-generation cephalosporins to be appropriate. Thirdgeneration cephalosporins are recommended for empirical therapy in CAP or as an alternative antimicrobial in CAPP. However, some data suggest that broad-spectrum cephalosporins have been associated with a higher risk for selection of penicillin- The strengths of the current study include its prospective design, the large cohort of consecutive hospitalized patients with CAPP and the comprehensive data collection. In addition, we evaluated the impact of antibiotic de-escalation on prognosis and other important clinical outcomes of CAP. Finally, we used multivariate analysis and a propensity score analysis to rule out possible confounding factors in the relation between antibiotic de-escalation and outcomes. However, the present study also has some limitations that should be acknowledged. Caution should be taken in the interpretation of some of our results because the de-escalation group was characterized by a less severe presentation at admission and more frequent de-escalation to an oral antibiotic. The present study was not a randomized trial; as with any observational study, there is potential for residual confounding despite multivariate analysis. Moreover, the study was performed at a single institution and some of the subgroups analysed comprised only a few patients. The number of patients admitted to the ICU who underwent de-escalation therapy was also small. Finally, it is likely that some cases of CAPP were not detected because the urinary antigen tests were not available in the first years of the study.
In conclusion, antibiotic de-escalation within the first 72 h after hospital admission seems to be safe and effective in reducing the duration of LOS, and did not adversely affect outcomes of patients with CAPP, even those with bacteraemia and severe disease, and those who were clinically unstable. Our results suggest that de-escalation strategies should be more widely implemented in the management of hospitalized adults with CAPP.
